Moderna stock crashes 25%, loses about $24 billion after cancer vaccine data leak

Moderna’s stock price dropped over 25% after trial results for its personalized melanoma vaccine with Merck were disclosed. The decline erased approximately $24 billion from Moderna’s market value, ending a significant rally this year. Analysts noted that this reaction was expected as investors…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.